Autolus Therapeutics (NASDAQ:AUTL) Shares Down 3.5% After Analyst Downgrade

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL)’s share price traded down 3.5% during mid-day trading on Wednesday after Wells Fargo & Company lowered their price target on the stock from $6.00 to $5.00. Wells Fargo & Company currently has an overweight rating on the stock. Autolus Therapeutics traded as low as $2.02 and last traded at $2.09. 579,562 shares traded hands during mid-day trading, a decline of 67% from the average session volume of 1,774,031 shares. The stock had previously closed at $2.16.

Separately, Needham & Company LLC reiterated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, July 21st. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Autolus Therapeutics presently has an average rating of “Buy” and an average price target of $9.12.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC bought a new position in shares of Autolus Therapeutics in the fourth quarter worth approximately $26,000. Barclays PLC grew its holdings in shares of Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company’s stock worth $28,000 after purchasing an additional 10,866 shares during the last quarter. R Squared Ltd bought a new position in shares of Autolus Therapeutics in the second quarter worth approximately $50,000. Delaney Dennis R bought a new stake in Autolus Therapeutics in the second quarter valued at $55,000. Finally, Virtus ETF Advisers LLC boosted its holdings in Autolus Therapeutics by 29.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company’s stock valued at $62,000 after acquiring an additional 6,081 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Down 14.4%

The firm has a market cap of $489.70 million, a P/E ratio of -2.19 and a beta of 1.90. The firm’s fifty day moving average is $2.34 and its two-hundred day moving average is $1.90.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.06. The company had revenue of $13.50 million during the quarter, compared to the consensus estimate of $12.92 million. As a group, sell-side analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.